Financial Times (11.03.09) - Tuesday, November 10, 2009
Andrew Jack

"By being 100 percent dedicated to HIV, we will reach more patients and do much more than either company on its own, with more products, more outreach and more focus," said Dominique Limet, CEO of ViiV.

ViiV combines GSK's well-established line of HIV medicines with Pfizer's portfolio, which includes many drugs still in development. With its own drugs moving toward the point at which their patents will expire, GSK's participation in the venture can boost its sales, marketing, and manufacturing. Pfizer can tap into GSK's infrastructure as it refocuses energies and cuts costs. In addition, a smaller, focused company can fuel innovation by allowing "nimbler responses," Limet said.

Some advocates, however, wonder whether the joint venture is to be sold off, with GSK and Pfizer following Roche's lead in leaving the HIV market. For instance, ViiV is not approaching third parties about combining treatments - an approach taken by its competitor and HIV drug market leader, Gilead. Atripla is a combination treatment of drugs owned by Gilead and Bristol-Myers Squibb. When asked, Limet said there are no current talks with other partners to license their therapies, nor is ViiV seeking external funders or non-executive directors from outside the parent companies.

"We want to know if they're trying to spin off a less profitable line to focus on more lucrative targets," said Mark Herrington, head of New York-based Treatment Action Group. "We'd love to be proved wrong here. With ever earlier recommendations to treat HIV, novel compounds for treatment and prevention are urgently needed."
091110
AD091926

Copyright © 2009 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.